LMY-922 for Refractory Autoimmune Disease
This study is testing a new cell therapy called LMY-922 for people with severe autoimmune diseases like Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM), and Systemic Sclerosis (SSc) that haven't responded to other treatments. LMY-922 is a type of CAR-T cell therapy, which uses your own modified immune cells to target and remove certain B cells that contribute to these diseases. The main goals are to see how safe LMY-922 is and to find the best dose. You may be able to join if you are between 16 and 75 years old and have one of the listed autoimmune conditions. The study plans to enroll 94 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive the LMY-922 therapy. The study aims to find a safe dose and will enroll up to 94 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety and dose-limiting toxicities for up to 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the Incidence and Severity of Treatment-Emergent Adverse Events (Safety) of LMY-922 in Patients ≥16 Years of Age with Refractory Autoimmune Disease24 Months
Incidence and severity of treatment-emergent adverse events
- To determine the recommended Phase II dose of LMY-922 based on Incidence of dose limiting toxicities in patients with refractory autoimmune disease.24 Months
Incidence of dose limiting toxicities (DLT)